Skip to Content

Generic Navelbine Availability

Navelbine is a brand name of vinorelbine, approved by the FDA in the following formulation(s):

NAVELBINE (vinorelbine tartrate - injectable;injection)

  • Manufacturer: PIERRE FABRE
    Approval date: December 23, 1994
    Strength(s): EQ 10MG BASE/ML [RLD] [AP]

Has a generic version of Navelbine been approved?

Yes. The following products are equivalent to Navelbine:

vinorelbine tartrate injectable;injection

  • Manufacturer: ACTAVIS TOTOWA
    Approval date: July 22, 2009
    Strength(s): EQ 10MG BASE/ML [AP]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: September 12, 2013
    Strength(s): EQ 10MG BASE/ML [AP]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: April 18, 2005
    Strength(s): EQ 10MG BASE/ML [AP]
  • Manufacturer: HOSPIRA
    Approval date: June 2, 2005
    Strength(s): EQ 10MG BASE/ML [AP]
  • Manufacturer: JIANGSU HANSOH PHARM
    Approval date: September 26, 2012
    Strength(s): EQ 10MG BASE/ML [AP]
  • Manufacturer: TEVA PHARMS USA
    Approval date: February 3, 2003
    Strength(s): EQ 10MG BASE/ML [AP]
  • Manufacturer: WEST-WARD PHARMS INT
    Approval date: June 10, 2003
    Strength(s): EQ 10MG BASE/ML [AP]
  • Manufacturer: WEST-WARD PHARMS INT
    Approval date: December 11, 2003
    Strength(s): EQ 10MG BASE/ML [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Navelbine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.